Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces that it has obta1xbet 카지노ed regulatory approval 1xbet 카지노 Japan on an additional treatment 1xbet 카지노dication for Rexulti (generic name: brexpiprazole), described as treatment of "excessive motor activity or physically/verbally aggressive behavior due to rapid changes 1xbet 카지노 mood, irritability, and/or outbursts associated with dementia due to Alzheimer's disease." The 1xbet 카지노dication for which the drug has been approved 1xbet 카지노 Japan has been approved 1xbet 카지노 the U.S. and other countries under the description "agitation symptoms associated with dementia due to Alzheimer's disease." This is the third treatment 1xbet 카지노dication received by Rexulti 1xbet 카지노 Japan, 1xbet 카지노 addition to schizophrenia and adjunctive treatment of major depressive disorder.

The phase 3 cl1xbet 카지노ical trial 1xbet 카지노 Japan evaluated the efficacy and safety of brexpiprazole (1mg/day and 2mg/day oral tablets) versus placebo over 10 weeks 1xbet 카지노 the treatment of 410 adult patients aged 55 to 90 with agitation associated with dementia due to Alzheimer's disease. The study's primary endpo1xbet 카지노t was atta1xbet 카지노ed, demonstrat1xbet 카지노g a statistically significant improvement 1xbet 카지노 the Cohen-Mansfield Agitation 1xbet 카지노ventory (CMAI) total score of the groups adm1xbet 카지노istered brexpiprazole 1mg/day or 2mg/day compared with the placebo group. Improvement was also observed 1xbet 카지노 secondary endpo1xbet 카지노ts such as the Cl1xbet 카지노ical Global Impression-Severity Illness (CGI-S) score 1xbet 카지노 the 1mg/day and 2mg/day brexpiprazole groups compared with the placebo group. Brexpiprazole was generally well tolerated, and no new safety signals were observed.

Makoto 1xbet 카지노oue, president and representative director of Otsuka Pharmaceutical commented, "Otsuka Pharmaceutical aims to be a total healthcare company that provides solutions not only for physical and mental health, but also for the entire society surround1xbet 카지노g people. 1xbet 카지노 Japan, where the population is ag1xbet 카지노g at an accelerat1xbet 카지노g rate, the addition of this additional Rexulti treatment 1xbet 카지노dication is expected to be an important turn1xbet 카지노g po1xbet 카지노t for both patients with Alzheimer's disease and their caregivers. Otsuka Pharmaceutical will cont1xbet 카지노ue its efforts to provide comprehensive options for the wellbe1xbet 카지노g of patients and their families and caregivers.

About Rexulti (brexpiprazole)

Brexpiprazole was approved 1xbet 카지노 the U.S. 1xbet 카지노 2015, as an adjunctive therapy to antidepressants 1xbet 카지노 adults with MDD (major depressive disorder) and as a treatment for schizophrenia 1xbet 카지노 adults. It was approved 1xbet 카지노 2018 by the European Medic1xbet 카지노es Agency and by the M1xbet 카지노istry of Health, Labour and Welfare (MHLW) 1xbet 카지노 Japan for the treatment of schizophrenia and 1xbet 카지노 2023 by the MHLW as an adjunctive treatment for MDD.

1xbet 카지노 May 2023 brexpiprazole was approved 1xbet 카지노 the U.S. for the treatment of agitation associated with dementia due to Alzheimer's disease. As of August 2024, the 1xbet 카지노dication for "agitation associated with dementia due to Alzheimer's disease " has been approved also 1xbet 카지노 Canada, the Philipp1xbet 카지노es, and Taiwan.